Retrophin ups guidance Citing robust reimbursement for Chenodal and success in finding undiagnosed cerebrotendinous xanthomatosis (CTX) patients, Retrophin ( OTC:RTRX ) ups its guidance for 2014 and 2015 to $19M - $21M (up from $10 - $12M) and $35M - $40M (up from $19M - $21M), respectively. The FDA declines to approve a clinical trial for RE-024 through an investigator-sponsored IND. The company will file its own by ...
April 14, 2014 - Seeking Alpha